Richard A. Schnizer

Array ( [id] => 11323883 [patent_doc_number] => 20160354493 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-08 [patent_title] => 'MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/240656 [patent_app_country] => US [patent_app_date] => 2016-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 117023 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15240656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11442003 [patent_doc_number] => 20170043024 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY' [patent_app_type] => utility [patent_app_number] => 15/236051 [patent_app_country] => US [patent_app_date] => 2016-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 73 [patent_figures_cnt] => 73 [patent_no_of_words] => 26826 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15236051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12099393 [patent_doc_number] => 09856481 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-02 [patent_title] => 'MicroRNA treatment of fibrosis' [patent_app_type] => utility [patent_app_number] => 15/235682 [patent_app_country] => US [patent_app_date] => 2016-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 38 [patent_no_of_words] => 15660 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15235682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12185748 [patent_doc_number] => 20180044685 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'APPLICATION OF SYK SERVING AS THERAPEUTIC TARGET FOR HEPATIC FIBROSIS/HEPATIC CIRRHOSIS' [patent_app_type] => utility [patent_app_number] => 15/554087 [patent_app_country] => US [patent_app_date] => 2016-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 2343 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15554087 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622843 [patent_doc_number] => 20180362973 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2018-12-20 [patent_title] => RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy [patent_app_type] => utility [patent_app_number] => 15/232493 [patent_app_country] => US [patent_app_date] => 2016-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50407 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15232493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622843 [patent_doc_number] => 20180362973 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2018-12-20 [patent_title] => RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy [patent_app_type] => utility [patent_app_number] => 15/232493 [patent_app_country] => US [patent_app_date] => 2016-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50407 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15232493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12255299 [patent_doc_number] => 09927441 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2018-03-27 [patent_title] => 'Combinatorial methods for aptamer based proteomics' [patent_app_type] => utility [patent_app_number] => 15/223062 [patent_app_country] => US [patent_app_date] => 2016-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 7 [patent_no_of_words] => 4812 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 198 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15223062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12470160 [patent_doc_number] => 09988636 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-05 [patent_title] => SDF-1 binding nucleic acids and the use thereof [patent_app_type] => utility [patent_app_number] => 15/219891 [patent_app_country] => US [patent_app_date] => 2016-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 49 [patent_no_of_words] => 47918 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15219891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11457376 [patent_doc_number] => 20170051282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-23 [patent_title] => 'EXTRACELLULAR VESICLE METHODS AND COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 15/217455 [patent_app_country] => US [patent_app_date] => 2016-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 35411 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15217455 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13814389 [patent_doc_number] => 10183955 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-22 [patent_title] => Molecules for isolation of polyribosomes, ribosomes, uses and kits thereof [patent_app_type] => utility [patent_app_number] => 15/744976 [patent_app_country] => US [patent_app_date] => 2016-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 19150 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15744976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16305607 [patent_doc_number] => 10774386 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-15 [patent_title] => Serum or plasma microRNA as biomarkers for non-small cell lung cancer [patent_app_type] => utility [patent_app_number] => 15/206797 [patent_app_country] => US [patent_app_date] => 2016-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 10 [patent_no_of_words] => 8286 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15206797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13154439 [patent_doc_number] => 10093934 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-09 [patent_title] => SDF-1 binding nucleic acids and the use thereof in cancer treatment [patent_app_type] => utility [patent_app_number] => 15/201477 [patent_app_country] => US [patent_app_date] => 2016-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 23 [patent_no_of_words] => 33893 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15201477 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15493311 [patent_doc_number] => 20200046844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => PEPTIDE-POLYNUCLEOTIDE COMPLEX FOR POLYNUCLEOTIDE TRANSFECTION [patent_app_type] => utility [patent_app_number] => 15/738478 [patent_app_country] => US [patent_app_date] => 2016-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20628 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15738478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15455015 [patent_doc_number] => 20200040332 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS [patent_app_type] => utility [patent_app_number] => 15/739366 [patent_app_country] => US [patent_app_date] => 2016-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11387 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15739366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12100271 [patent_doc_number] => 09857362 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-02 [patent_title] => 'Method for preparing nucleic acid aptamer' [patent_app_type] => utility [patent_app_number] => 15/188297 [patent_app_country] => US [patent_app_date] => 2016-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 23 [patent_no_of_words] => 21203 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15188297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11561902 [patent_doc_number] => 09624476 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-18 [patent_title] => 'Conditionally replicating adenovirus' [patent_app_type] => utility [patent_app_number] => 15/183661 [patent_app_country] => US [patent_app_date] => 2016-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 10 [patent_no_of_words] => 19844 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15183661 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16336717 [patent_doc_number] => 10787664 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-29 [patent_title] => Compounds of chemically modified oligonucleotides and methods of use thereof [patent_app_type] => utility [patent_app_number] => 15/163816 [patent_app_country] => US [patent_app_date] => 2016-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 92 [patent_no_of_words] => 21923 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15163816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12166286 [patent_doc_number] => 09885049 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-06 [patent_title] => 'Modulation of pre-MRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease' [patent_app_type] => utility [patent_app_number] => 15/160438 [patent_app_country] => US [patent_app_date] => 2016-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 16 [patent_no_of_words] => 33300 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15160438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11046288 [patent_doc_number] => 20160243246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-25 [patent_title] => 'HYALURONIC ACID-NUCLEIC ACID CONJUGATE AND COMPOSITION FOR NUCLEIC ACID DELIVERY CONTAINING THE SAME' [patent_app_type] => utility [patent_app_number] => 15/151632 [patent_app_country] => US [patent_app_date] => 2016-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 9115 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15151632 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17408192 [patent_doc_number] => 11249071 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => Reactivation of x chromosome genes [patent_app_type] => utility [patent_app_number] => 15/138208 [patent_app_country] => US [patent_app_date] => 2016-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 72 [patent_figures_cnt] => 90 [patent_no_of_words] => 25222 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15138208 [rel_patent_id] =>[rel_patent_doc_number] =>)